Assessment of Anticoagulation Using Activated Clotting Times in Patients Receiving Intravenous Enoxaparin during Percutaneous Coronary Intervention

Catheterization and Cardiovascular Interventions

Volumn 61, Issue 1, 2004, Pages 52-55

  Lawrence, Mark ^a,b   Mixon, Timothy A ^a,b   Cross, Donald ^a,b   Gant, D Scott ^a,b   Dehmer, Gregory J ^a,b  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b TEXAS A AND M UNIVERSITY SYSTEM   (United States)

Author keywords

Angioplasty; Antithrombotic therapy; Low molecular weight heparin

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; EPTIFIBATIDE;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE THROMBOSIS; REVASCULARIZATION; STATISTICAL SIGNIFICANCE; THROMBOGENESIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; BLOOD COAGULATION; CORONARY THROMBOSIS; ENOXAPARIN; HUMANS; INFUSIONS, INTRAVENOUS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; WHOLE BLOOD COAGULATION TIME;

EID: 0347992845     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10683     Document Type: Article

References (27)

1. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, de Bono D, Ferguson J, Willerson JT, Strony J. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993;87:1622-1629.
2. Narins CR, Hillegass WB, Nelson CL, Tcheng JE, Harrington RA, Phillips HR, Stack RS, Califf RM. Relationship between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:667-671.
3. Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, Marsh KC, Leachman DR. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:1061-1065.
4. Tolleson TR, O'Shea JC, Bittl JA, Hillegass WB, Willimas KA, Levine G, Harrington RA, Tcheng JE. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention. J Am Coll Cardiol 2003;41:386-393.
5. Fergusson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA, Pepine CJ, Theroux P. The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: final results of the NICE 3 study. J Am Coll Cardiol 2001;37:365A.
6. Young JJ, Kereiakes DJ, Grines CL, for the National Investigators Collaborating on Enoxaparin (NICE). Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. J Invas Cardiol 2000;12(Suppl E):E14-E18.
7. Hirsh J, Levine MN. Low molecular weight heparins. Blood 1992;79:1-17.
8. Hirsh J. Heparin. N Engl J Med 1991;324:1565-1574.
9. Brace LD, Issleib S, Fared J. Heparin-induced platelet aggregation is inhibited by antiagonists of the thromboxane pathway. Thromb Res 1985;39:533-537.
10. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995;332:1330-1336.
11. Loscalzo J, Melnick B, Handin R. The interaction of platelet factor four and glycosaminoglycans. Arch Biochem Biophys 1985;240:446-455.
12. Padilla A, Gray E, Pepper DS, Barrowcliffe TW. Inhibition of thrombin generation by heparin and low molecular weight heparins in the absence and presence of platelet factor 4 (PF4). Br J Haematol 1992;82:406-413.
13. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular weight heparin and with direct thrombin inhibitor. Circulation 1998;97:251-256.
14. ESPRIT investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized placebo-controlled trial. Lancet 2000;356:2037-2044.
15. Kereiakes DJ, Grines CL, Fry E, Esente P, Hoppensteadt D, Midei M, Barr L, Matthai W, Todd M, Broderick T, Rubinstein R, Fareed J, Santoian E, Neiderman A, Brodie B, Zidar J, Ferguson JJ, Cohen M, for the NICE 1 and NICE 4 investigators. Enoxaparin and abciximab adjunctive therapy pharmacotherapy during percutaneous coronary intervention. J Inv Cardiol 2001;13:272-278.
16. Collet JP, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski G, Sotirov I, Thomas D. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103:658-663.
17. Martin JL, Fry ETA, Serano A, Atherley TH, Ozoux ML, Guimart C, Chevalier P, Bigonzi F, Pensyl C, Sanderink GJ. Pharmacokinetic study of enoxaparin in patients undergoing coronary intervention after treatment with subcutaneous enoxaparin in acute coronary syndromes (PEPC1) study. Eur Heart J 2001;22:143.
18. Henry TD, Satran D, Knox LL, Iacarella CL, Laxson DD, Antman EM. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin? Am Heart J 2001;142:590-593.
19. Rabah MM, Premmereur J, Graham M, Fareed J, Hoppensteadt DA, Grines LL, Grines CL. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am J Cardiol 1999;84:1391-1395.
20. Chen W, Lau C, Lau Y, Ng W, Lee P, Yu C, Ma E. Stable and optimal anticoagulation is achieved with a single dose of intravenous enoxaparin in patients undergoing percutaneous coronary intervention. J Invas Cardiol 2002;14:439-442.
21. Marmur JD, Anand SX, Bagga RS, Fareed J, Pan CM, Sharma SK, Richard MF. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol 2003;41:394-402.
22. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanism of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94S.
23. Weitz JI. Low molecular weight heparins. N Engl J Med 1997;337:688-698.
24. Abbate R, Gori AM, Farsi A, Attanasid M, Pepe G. Monitoring of low-molecular-weight heparins in cardiovascular disease. Am J Cardiol 1998;82:33L-36L.
25. Smith BS, Gandhi PH. Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonists in renal failure. J Thromb Thrombolysis 2001;11:39-48.
26. ASSENT-3 investigators. Efficacy and safety of tenecteplace in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. Lancet 2001;358:605-613.
27. Choussat R, Montalescot G, Collet JP, Vicaut E, Ankri A, Gallois V, Drobinski G, Sotirov I, Thomas D. A unique low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 2002;40:1943-1950.